Polymyositis and dermatomyositis laboratory findings: Difference between revisions

	Polymyositis and dermatomyositis Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Polymyositis and dermatomyositis from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Polymyositis and dermatomyositis laboratory findings On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Polymyositis and dermatomyositis laboratory findings All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Polymyositis and dermatomyositis laboratory findings
CDC on Polymyositis and dermatomyositis laboratory findings
Polymyositis and dermatomyositis laboratory findings in the news
Blogs on Polymyositis and dermatomyositis laboratory findings
Directions to Hospitals Treating Psoriasis
Risk calculators and risk factors for Polymyositis and dermatomyositis laboratory findings

VisualWikitext

Latest revision as of 13:20, 4 June 2018

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sadaf Sharfaei M.D.[2]

Overview

Elevated sarcoplasmic enzymes are consistent with the diagnosis of polymyositis and dermatomyositis which include creatine phosphokinase, aldolase, transaminases, lactic dehydrogenase, and myoglobin. High white blood cell counts, low lymphocytes, and low hematocrit levels might be detected on CBC. Low albumin levels, high ESR and high IgM and IgG levels could be seen in patients with polymyositis and dermatomyositis. 20 myositis-specific autoantibodies are identified in patients with polymyositis and dermatomyositis. Anti-Jo-1 antibody is the most frequent myositis-specific autoantibodies which causes antisynthetase syndrome. Anti Mi-2 might be seen frequently in patients with dermatomyositis. Anti-SRP antibody is associated with very poor prognosis. Some of these myositis-specific autoantibodies are associated with malignancy. Anti-HMGCR antibody might be elevated in patients with statin-associated necrotizing autoimmune myopathy (SANAM).

Laboratory Findings

Different laboratory tests may be used to diagnose polymyositis and dermatomyositis and exclude other myopathies which include:^[1]^[2]^[3]^[4]^[5]^[6]^[7]^[8]
- Routine tests^[9]
- Sarcoplasmic enzymes
- Myositis-specific autoantibodies^[10]^[11]

Routine test

Abnormal test results include:
- CBC
  - High white blood cell counts
  - Low lymphocyte counts
  - Low hematocrit levels
- Low albumin levels
- High erythrocyte sedimentation rate
- High IgM and IgG levels

Sarcoplasmic enzymes

Sarcoplasmic enzymes consistent with the diagnosis of polymyositis and dermatomyositis include:^[12]
- Creatine phosphokinase including:
  - CK-MM
  - CK-MB
- Aldolase
- Transaminases
  - Alanine aminotransferase
  - Aspartate aminotransferase
- Lactic dehydrogenase
- Myoglobin

Myositis-specific autoantibodies

Autoantibody		Antigen	Features	Frequency
Antisynthetase	Anti-Jo-1	Histidyl-tRNA synthetase	Antisynthetase syndrome Arthritis Interstitial lung disease Fever Mechanic's hands Raynaud's phenomenon Flare up in spring Moderate response to treatment Poor prognosis Associated with epstein-Barr virus (EBV), adenovirus, and influenza infection	20-25%
	Anti-PL-7	Threonyl-tRNA synthetase	Myositis, mechanic's hands, Gottron's papules, arthritis	5-10%
	Anti PL-12	Alanyl-tRNA synthetase	Fever, Raynaud's phenomenon, high frequency of ILD Epstein-Barr virus (EBV), adenovirus, and influenza infection	<5%
	Anti PL-12	Alanyl-tRNA		<5%
	Anti-EJ	Glycyl-tRNA synthetase		5-10%
	Anti-OJ	Isoleucyl-tRNA synthetase		<5%
	Anti-KS	Asparaginyl-tRNA synthetase		<5%
	Anti-Ha	Tyrosyl-tRNA synthetase		<1%
	Anti-Zo	Phenylalanyl-tRNA synthetase		<1%
Others	Anti Mi-2	Chromodomain helicase DNA binding protein 4	Dermatomyositis rash without significant lung involvement Acute but mild onset Good prognosis	5-10%
	Anti-SRP	Signal recognition particle	Cardiac involvement Necrotizing myopathy Flare up in fall Very acute and severe onset Poor response to treatment Very poor prognosis	<5%
	Anti-p155/140	Transcriptional intermediary factor 1-gamma	Cancer-associated myositis Juvenile dermatomyositis Severe cutaneous disease	13-21% in IIM 23-29% in JDM
	Anti-MJ	Nuclear matrix protein (NXP-2)	Cancer-associated myositis Juvenile dermatomyositis	23% in JDM
	Anti-SAE	Small ubiquitin-like modifier activating enzyme	Cancer-associated myositis	5%
	Anti-caDM-140	Intracytoplasmic MDA5	Dermatomyositis and rapidly progressive ILD	50% (C-ADM)
	Anti-PMS1	DNA mismatch repair enzyme		7.5%
	Anti-HMGCR	3-hydroxy-3-methylglutaryl-coenzyme A reductase	Statin-associated necrotizing autoimmune myopathy (SANAM)	6%
	Anti-FER	Elongation factor 1 alpha
	Anti-KJ	Unidentified cytoplasmic protein
	Anti-MAS	Unidentified cytoplasmic RNA
	Anti–PM-Scl		Overlap of polymyositis and Scleroderma	25%

References

↑ Adler BL, Christopher-Stine L (February 2018). "Triggers of inflammatory myopathy: insights into pathogenesis". Discov Med. 25 (136): 75–83. PMID 29579414.
↑ Bodoki L, Nagy-Vincze M, Griger Z, Betteridge Z, Szöllősi L, Dankó K (December 2014). "Four dermatomyositis-specific autoantibodies-anti-TIF1γ, anti-NXP2, anti-SAE and anti-MDA5-in adult and juvenile patients with idiopathic inflammatory myopathies in a Hungarian cohort". Autoimmun Rev. 13 (12): 1211–9. doi:10.1016/j.autrev.2014.08.011. PMID 25182203.
↑ Khan, Sabiha; Christopher-Stine, Lisa (2011). "Polymyositis, Dermatomyositis, and Autoimmune Necrotizing Myopathy: Clinical Features". Rheumatic Disease Clinics of North America. 37 (2): 143–158. doi:10.1016/j.rdc.2011.01.001. ISSN 0889-857X.
↑ Dobloug, Cecilie; Garen, Torhild; Bitter, Helle; Stjärne, Johan; Stenseth, Guri; Grøvle, Lars; Sem, Marthe; Gran, Jan Tore; Molberg, Øyvind (2015). "Prevalence and clinical characteristics of adult polymyositis and dermatomyositis; data from a large and unselected Norwegian cohort". Annals of the Rheumatic Diseases. 74 (8): 1551–1556. doi:10.1136/annrheumdis-2013-205127. ISSN 0003-4967.
↑ Chinoy, H.; Fertig, N.; Oddis, C. V; Ollier, W. E R; Cooper, R. G (2007). "The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis". Annals of the Rheumatic Diseases. 66 (10): 1345–1349. doi:10.1136/ard.2006.068502. ISSN 0003-4967.
↑ Dalakas, Marinos C; Hohlfeld, Reinhard (2003). "Polymyositis and dermatomyositis". The Lancet. 362 (9388): 971–982. doi:10.1016/S0140-6736(03)14368-1. ISSN 0140-6736.
↑ Douglas, William W.; Tazelaar, Henry D.; Hartman, Thomas E.; Hartman, Robert P.; Decker, Paul A.; Schroeder, Darrell R.; Ryu, Jay H. (2001). "Polymyositis–Dermatomyositis-associated Interstitial Lung Disease". American Journal of Respiratory and Critical Care Medicine. 164 (7): 1182–1185. doi:10.1164/ajrccm.164.7.2103110. ISSN 1073-449X.
↑ Miller, Frederick W. (1993). "Myositis-Specific Autoantibodies". JAMA. 270 (15): 1846. doi:10.1001/jama.1993.03510150080034. ISSN 0098-7484.
↑ Volochayev, Rita (2012). "Laboratory Test Abnormalities are Common in Polymyositis and Dermatomyositis and Differ Among Clinical and Demographic Groups". The Open Rheumatology Journal. 6 (1): 54–63. doi:10.2174/1874312901206010054. ISSN 1874-3129.
↑ Targoff, Ira N. (2006). "Myositis specific autoantibodies". Current Rheumatology Reports. 8 (3): 196–203. doi:10.1007/s11926-996-0025-3. ISSN 1523-3774.
↑ Gunawardena, H.; Betteridge, Z. E.; McHugh, N. J. (2009). "Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression". Rheumatology. 48 (6): 607–612. doi:10.1093/rheumatology/kep078. ISSN 1462-0324.
↑ Bohan, Anthony; Peter, James B. (1975). "Polymyositis and Dermatomyositis". New England Journal of Medicine. 292 (8): 403–407. doi:10.1056/NEJM197502202920807. ISSN 0028-4793.

[pmid29579414-1] Adler BL, Christopher-Stine L (February 2018). "Triggers of inflammatory myopathy: insights into pathogenesis". Discov Med. 25 (136): 75–83. PMID 29579414.

[pmid25182203-2] Bodoki L, Nagy-Vincze M, Griger Z, Betteridge Z, Szöllősi L, Dankó K (December 2014). "Four dermatomyositis-specific autoantibodies-anti-TIF1γ, anti-NXP2, anti-SAE and anti-MDA5-in adult and juvenile patients with idiopathic inflammatory myopathies in a Hungarian cohort". Autoimmun Rev. 13 (12): 1211–9. doi:10.1016/j.autrev.2014.08.011. PMID 25182203.

[KhanChristopher-Stine2011-3] Khan, Sabiha; Christopher-Stine, Lisa (2011). "Polymyositis, Dermatomyositis, and Autoimmune Necrotizing Myopathy: Clinical Features". Rheumatic Disease Clinics of North America. 37 (2): 143–158. doi:10.1016/j.rdc.2011.01.001. ISSN 0889-857X.

[DoblougGaren2015-4] Dobloug, Cecilie; Garen, Torhild; Bitter, Helle; Stjärne, Johan; Stenseth, Guri; Grøvle, Lars; Sem, Marthe; Gran, Jan Tore; Molberg, Øyvind (2015). "Prevalence and clinical characteristics of adult polymyositis and dermatomyositis; data from a large and unselected Norwegian cohort". Annals of the Rheumatic Diseases. 74 (8): 1551–1556. doi:10.1136/annrheumdis-2013-205127. ISSN 0003-4967.

[ChinoyFertig2007-5] Chinoy, H.; Fertig, N.; Oddis, C. V; Ollier, W. E R; Cooper, R. G (2007). "The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis". Annals of the Rheumatic Diseases. 66 (10): 1345–1349. doi:10.1136/ard.2006.068502. ISSN 0003-4967.

[DalakasHohlfeld2003-6] Dalakas, Marinos C; Hohlfeld, Reinhard (2003). "Polymyositis and dermatomyositis". The Lancet. 362 (9388): 971–982. doi:10.1016/S0140-6736(03)14368-1. ISSN 0140-6736.

[DouglasTazelaar2001-7] Douglas, William W.; Tazelaar, Henry D.; Hartman, Thomas E.; Hartman, Robert P.; Decker, Paul A.; Schroeder, Darrell R.; Ryu, Jay H. (2001). "Polymyositis–Dermatomyositis-associated Interstitial Lung Disease". American Journal of Respiratory and Critical Care Medicine. 164 (7): 1182–1185. doi:10.1164/ajrccm.164.7.2103110. ISSN 1073-449X.

[Miller1993-8] Miller, Frederick W. (1993). "Myositis-Specific Autoantibodies". JAMA. 270 (15): 1846. doi:10.1001/jama.1993.03510150080034. ISSN 0098-7484.

[Volochayev2012-9] Volochayev, Rita (2012). "Laboratory Test Abnormalities are Common in Polymyositis and Dermatomyositis and Differ Among Clinical and Demographic Groups". The Open Rheumatology Journal. 6 (1): 54–63. doi:10.2174/1874312901206010054. ISSN 1874-3129.

[Targoff2006-10] Targoff, Ira N. (2006). "Myositis specific autoantibodies". Current Rheumatology Reports. 8 (3): 196–203. doi:10.1007/s11926-996-0025-3. ISSN 1523-3774.

[GunawardenaBetteridge2009-11] Gunawardena, H.; Betteridge, Z. E.; McHugh, N. J. (2009). "Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression". Rheumatology. 48 (6): 607–612. doi:10.1093/rheumatology/kep078. ISSN 1462-0324.

[BohanPeter1975-12] Bohan, Anthony; Peter, James B. (1975). "Polymyositis and Dermatomyositis". New England Journal of Medicine. 292 (8): 403–407. doi:10.1056/NEJM197502202920807. ISSN 0028-4793.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

[12]

@@ Line 5: / Line 5: @@
 ==Overview==
+Elevated [[Sarcoplasmic reticulum|sarcoplasmic]] enzymes are consistent with the diagnosis of polymyositis and dermatomyositis which include [[Creatine kinase|creatine phosphokinase]], [[aldolase]], [[Transaminase|transaminases]], [[Lactate dehydrogenase|lactic dehydrogenase]], and [[myoglobin]]. High [[White blood cells|white blood cell]] counts, low [[Lymphocyte|lymphocytes]], and low [[hematocrit]] levels might be detected on [[Complete blood count|CBC]]. Low [[albumin]] levels, high [[Erythrocyte sedimentation rate|ESR]] and high [[Immunoglobulin M|IgM]] and [[Immunoglobulin G|IgG]] levels could be seen in patients with polymyositis and dermatomyositis. 20 myositis-specific autoantibodies are identified in patients with polymyositis and dermatomyositis. Anti-Jo-1 antibody is the most frequent myositis-specific autoantibodies which causes antisynthetase syndrome. Anti Mi-2 might be seen frequently in patients with dermatomyositis. Anti-SRP antibody is associated with very poor prognosis. Some of these myositis-specific autoantibodies are associated with [[Cancer|malignancy]]. Anti-HMGCR antibody might be elevated in patients with statin-associated necrotizing autoimmune myopathy (SANAM).
 ==Laboratory Findings==
 *Different laboratory tests may be used to diagnose polymyositis and dermatomyositis and exclude other myopathies which include:<ref name="pmid29579414">{{cite journal |vauthors=Adler BL, Christopher-Stine L |title=Triggers of inflammatory myopathy: insights into pathogenesis |journal=Discov Med |volume=25 |issue=136 |pages=75–83 |date=February 2018 |pmid=29579414 |doi= |url=}}</ref><ref name="pmid25182203">{{cite journal |vauthors=Bodoki L, Nagy-Vincze M, Griger Z, Betteridge Z, Szöllősi L, Dankó K |title=Four dermatomyositis-specific autoantibodies-anti-TIF1γ, anti-NXP2, anti-SAE and anti-MDA5-in adult and juvenile patients with idiopathic inflammatory myopathies in a Hungarian cohort |journal=Autoimmun Rev |volume=13 |issue=12 |pages=1211–9 |date=December 2014 |pmid=25182203 |doi=10.1016/j.autrev.2014.08.011 |url=}}</ref><ref name="KhanChristopher-Stine2011">{{cite journal|last1=Khan|first1=Sabiha|last2=Christopher-Stine|first2=Lisa|title=Polymyositis, Dermatomyositis, and Autoimmune Necrotizing Myopathy: Clinical Features|journal=Rheumatic Disease Clinics of North America|volume=37|issue=2|year=2011|pages=143–158|issn=0889857X|doi=10.1016/j.rdc.2011.01.001}}</ref><ref name="DoblougGaren2015">{{cite journal|last1=Dobloug|first1=Cecilie|last2=Garen|first2=Torhild|last3=Bitter|first3=Helle|last4=Stjärne|first4=Johan|last5=Stenseth|first5=Guri|last6=Grøvle|first6=Lars|last7=Sem|first7=Marthe|last8=Gran|first8=Jan Tore|last9=Molberg|first9=Øyvind|title=Prevalence and clinical characteristics of adult polymyositis and dermatomyositis; data from a large and unselected Norwegian cohort|journal=Annals of the Rheumatic Diseases|volume=74|issue=8|year=2015|pages=1551–1556|issn=0003-4967|doi=10.1136/annrheumdis-2013-205127}}</ref><ref name="ChinoyFertig2007">{{cite journal|last1=Chinoy|first1=H.|last2=Fertig|first2=N.|last3=Oddis|first3=C. V|last4=Ollier|first4=W. E R|last5=Cooper|first5=R. G|title=The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis|journal=Annals of the Rheumatic Diseases|volume=66|issue=10|year=2007|pages=1345–1349|issn=0003-4967|doi=10.1136/ard.2006.068502}}</ref><ref name="DalakasHohlfeld2003">{{cite journal|last1=Dalakas|first1=Marinos C|last2=Hohlfeld|first2=Reinhard|title=Polymyositis and dermatomyositis|journal=The Lancet|volume=362|issue=9388|year=2003|pages=971–982|issn=01406736|doi=10.1016/S0140-6736(03)14368-1}}</ref><ref name="DouglasTazelaar2001">{{cite journal|last1=Douglas|first1=William W.|last2=Tazelaar|first2=Henry D.|last3=Hartman|first3=Thomas E.|last4=Hartman|first4=Robert P.|last5=Decker|first5=Paul A.|last6=Schroeder|first6=Darrell R.|last7=Ryu|first7=Jay H.|title=Polymyositis–Dermatomyositis-associated Interstitial Lung Disease|journal=American Journal of Respiratory and Critical Care Medicine|volume=164|issue=7|year=2001|pages=1182–1185|issn=1073-449X|doi=10.1164/ajrccm.164.7.2103110}}</ref><ref name="Miller1993">{{cite journal|last1=Miller|first1=Frederick W.|title=Myositis-Specific Autoantibodies|journal=JAMA|volume=270|issue=15|year=1993|pages=1846|issn=0098-7484|doi=10.1001/jama.1993.03510150080034}}</ref>
-**Sarcoplasmic enzymes
+**Routine tests<ref name="Volochayev2012">{{cite journal|last1=Volochayev|first1=Rita|title=Laboratory Test Abnormalities are Common in Polymyositis and Dermatomyositis and Differ Among Clinical and Demographic Groups|journal=The Open Rheumatology Journal|volume=6|issue=1|year=2012|pages=54–63|issn=18743129|doi=10.2174/1874312901206010054}}</ref>
+**[[Endoplasmic reticulum|Sarcoplasmic]] enzymes
 **Myositis-specific autoantibodies<ref name="Targoff2006">{{cite journal|last1=Targoff|first1=Ira N.|title=Myositis specific autoantibodies|journal=Current Rheumatology Reports|volume=8|issue=3|year=2006|pages=196–203|issn=1523-3774|doi=10.1007/s11926-996-0025-3}}</ref><ref name="GunawardenaBetteridge2009">{{cite journal|last1=Gunawardena|first1=H.|last2=Betteridge|first2=Z. E.|last3=McHugh|first3=N. J.|title=Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression|journal=Rheumatology|volume=48|issue=6|year=2009|pages=607–612|issn=1462-0324|doi=10.1093/rheumatology/kep078}}</ref>
+=== Routine test ===
+* Abnormal test results include:
+** [[Complete blood count|CBC]]
+*** High [[White blood cells|white blood cell]] counts
+*** Low [[lymphocyte]] counts
+*** Low [[hematocrit]] levels
+** Low [[albumin]] levels
+** High [[erythrocyte sedimentation rate]]
+** High [[Immunoglobulin M|IgM]] and [[Immunoglobulin G|IgG]] levels
 === Sarcoplasmic enzymes ===
-* Sarcoplasmic enzymes consistent with the diagnosis of polymyositis and dermatomyositis include:<ref name="BohanPeter1975">{{cite journal|last1=Bohan|first1=Anthony|last2=Peter|first2=James B.|title=Polymyositis and Dermatomyositis|journal=New England Journal of Medicine|volume=292|issue=8|year=1975|pages=403–407|issn=0028-4793|doi=10.1056/NEJM197502202920807}}</ref>
+* [[Endoplasmic reticulum|Sarcoplasmic]] enzymes consistent with the diagnosis of polymyositis and dermatomyositis include:<ref name="BohanPeter1975">{{cite journal|last1=Bohan|first1=Anthony|last2=Peter|first2=James B.|title=Polymyositis and Dermatomyositis|journal=New England Journal of Medicine|volume=292|issue=8|year=1975|pages=403–407|issn=0028-4793|doi=10.1056/NEJM197502202920807}}</ref>
-** Creatine phosphokinase
+** [[Creatine kinase|Creatine phosphokinase]] including:
-** Aldolase
+*** [[Creatine kinase|CK-MM]]
-** Transaminases
+*** [[Creatine kinase|CK-MB]]
-*** Alanine aminotransferase
+** [[Aldolase]]
-*** Aspartate aminotransferase
+** [[Transaminase|Transaminases]]
-** Lactic dehydrogenase
+*** [[Alanine transaminase|Alanine aminotransferase]]
+*** [[Aspartate transaminase|Aspartate aminotransferase]]
+** [[Lactate dehydrogenase|Lactic dehydrogenase]]
+** [[Myoglobin]]
 === Myositis-specific autoantibodies ===
@@ Line 27: / Line 42: @@
 |-
 | rowspan="9" align="left" style="background:#F5F5F5;" + |Antisynthetase
-| align="left" style="background:#F5F5F5;" + |Anti-Jo-1
+! align="left" style="background:#F5F5F5;" + |Anti-Jo-1
 | align="left" style="background:#F5F5F5;" + |Histidyl-tRNA synthetase
 | align="left" style="background:#F5F5F5;" + |
@@ Line 42: / Line 57: @@
 | align="left" style="background:#F5F5F5;" + |20-25%
 |-
-| align="left" style="background:#F5F5F5;" + |Anti-PL-7
+! align="left" style="background:#F5F5F5;" + |Anti-PL-7
 | align="left" style="background:#F5F5F5;" + |Threonyl-tRNA synthetase
 | align="left" style="background:#F5F5F5;" + |
@@ Line 48: / Line 63: @@
 | align="left" style="background:#F5F5F5;" + |5-10%
 |-
-| rowspan="2" align="left" style="background:#F5F5F5;" + |Anti PL-12
+! rowspan="2" align="left" style="background:#F5F5F5;" + |Anti PL-12
 | align="left" style="background:#F5F5F5;" + |Alanyl-tRNA synthetase
 | rowspan="2" align="left" style="background:#F5F5F5;" + |
@@ Line 57: / Line 72: @@
 | align="left" style="background:#F5F5F5;" + |Alanyl-tRNA
 |-
-| align="left" style="background:#F5F5F5;" + |Anti-EJ
+! align="left" style="background:#F5F5F5;" + |Anti-EJ
 | align="left" style="background:#F5F5F5;" + |Glycyl-tRNA synthetase
 | align="left" style="background:#F5F5F5;" + |
 | align="left" style="background:#F5F5F5;" + |5-10%
 |-
-| align="left" style="background:#F5F5F5;" + |Anti-OJ
+! align="left" style="background:#F5F5F5;" + |Anti-OJ
 | align="left" style="background:#F5F5F5;" + |Isoleucyl-tRNA synthetase
 | align="left" style="background:#F5F5F5;" + |
 | align="left" style="background:#F5F5F5;" + |<5%
 |-
-|Anti-KS
+! align="left" style="background:#F5F5F5;" + |Anti-KS
-|Asparaginyl-tRNA synthetase
+| align="left" style="background:#F5F5F5;" + |Asparaginyl-tRNA synthetase
-|
+| align="left" style="background:#F5F5F5;" + |
-|<5%
+| align="left" style="background:#F5F5F5;" + |<5%
 |-
-|Anti-Ha
+! align="left" style="background:#F5F5F5;" + |Anti-Ha
-|Tyrosyl-tRNA synthetase
+| align="left" style="background:#F5F5F5;" + |Tyrosyl-tRNA synthetase
-|
+| align="left" style="background:#F5F5F5;" + |
-|<1%
+| align="left" style="background:#F5F5F5;" + |<1%
 |-
-|Anti-Zo
+! align="left" style="background:#F5F5F5;" + |Anti-Zo
-|Phenylalanyl-tRNA synthetase
+| align="left" style="background:#F5F5F5;" + |Phenylalanyl-tRNA synthetase
-|
+| align="left" style="background:#F5F5F5;" + |
-|<1%
+| align="left" style="background:#F5F5F5;" + |<1%
 |-
-| align="left" style="background:#F5F5F5;" + |
+| rowspan="12" align="left" style="background:#F5F5F5;" + |Others
-| align="left" style="background:#F5F5F5;" + |Anti Mi-2
+! align="left" style="background:#F5F5F5;" + |Anti Mi-2
 | align="left" style="background:#F5F5F5;" + |Chromodomain helicase DNA binding protein 4
 | align="left" style="background:#F5F5F5;" + |
@@ Line 91: / Line 106: @@
 | align="left" style="background:#F5F5F5;" + |5-10%
 |-
-| align="left" style="background:#F5F5F5;" + |
+! align="left" style="background:#F5F5F5;" + |Anti-SRP
-| align="left" style="background:#F5F5F5;" + |Anti-SRP
 | align="left" style="background:#F5F5F5;" + |Signal recognition particle
 | align="left" style="background:#F5F5F5;" + |
@@ Line 103: / Line 117: @@
 | align="left" style="background:#F5F5F5;" + |<5%
 |-
-| align="left" style="background:#F5F5F5;" + |
+! align="left" style="background:#F5F5F5;" + |Anti-p155/140
-| align="left" style="background:#F5F5F5;" + |Anti-p155/140
 | align="left" style="background:#F5F5F5;" + |Transcriptional intermediary factor 1-gamma
 | align="left" style="background:#F5F5F5;" + |
@@ Line 114: / Line 127: @@
 -29% in JDM
 |-
-| align="left" style="background:#F5F5F5;" + |
+! align="left" style="background:#F5F5F5;" + |Anti-MJ
-| align="left" style="background:#F5F5F5;" + |Anti-MJ
 | align="left" style="background:#F5F5F5;" + |Nuclear matrix protein (NXP-2)
 | align="left" style="background:#F5F5F5;" + |
@@ Line 122: / Line 134: @@
 | align="left" style="background:#F5F5F5;" + |23% in JDM
 |-
-| align="left" style="background:#F5F5F5;" + |
+! align="left" style="background:#F5F5F5;" + |Anti-SAE
-| align="left" style="background:#F5F5F5;" + |Anti-SAE
 | align="left" style="background:#F5F5F5;" + |Small ubiquitin-like modifier activating enzyme
 | align="left" style="background:#F5F5F5;" + |
@@ Line 129: / Line 140: @@
 | align="left" style="background:#F5F5F5;" + |5%
 |-
-|
+! align="left" style="background:#F5F5F5;" + |Anti-caDM-140
-|Anti-caDM-140
+| align="left" style="background:#F5F5F5;" + |Intracytoplasmic MDA5
-|Intracytoplasmic MDA5
+| align="left" style="background:#F5F5F5;" + |
-|
 * Dermatomyositis and rapidly progressive ILD
-|50% (C-ADM)
+| align="left" style="background:#F5F5F5;" + |50% (C-ADM)
 |-
-|
+! align="left" style="background:#F5F5F5;" + |Anti-PMS1
-|Anti-PMS1
+| align="left" style="background:#F5F5F5;" + |DNA mismatch repair enzyme
-|DNA mismatch repair enzyme
+| align="left" style="background:#F5F5F5;" + |
-|
+| align="left" style="background:#F5F5F5;" + |7.5%
-|7.5%
 |-
-| align="left" style="background:#F5F5F5;" + |
+! align="left" style="background:#F5F5F5;" + |Anti-HMGCR
-| align="left" style="background:#F5F5F5;" + |Anti-HMGCR
 | align="left" style="background:#F5F5F5;" + |3-hydroxy-3-methylglutaryl-coenzyme A reductase
 | align="left" style="background:#F5F5F5;" + |
@@ Line 149: / Line 157: @@
 | align="left" style="background:#F5F5F5;" + |6%
 |-
-| rowspan="3" align="left" style="background:#F5F5F5;" + |Others
+! align="left" style="background:#F5F5F5;" + |Anti-FER
-| align="left" style="background:#F5F5F5;" + |Anti-FER
 | align="left" style="background:#F5F5F5;" + |Elongation factor 1 alpha
 | align="left" style="background:#F5F5F5;" + |
 | align="left" style="background:#F5F5F5;" + |
 |-
-| align="left" style="background:#F5F5F5;" + |Anti-KJ
+! align="left" style="background:#F5F5F5;" + |Anti-KJ
 | align="left" style="background:#F5F5F5;" + |Unidentified cytoplasmic protein
 | align="left" style="background:#F5F5F5;" + |
 | align="left" style="background:#F5F5F5;" + |
 |-
-| align="left" style="background:#F5F5F5;" + |Anti-MAS
+! align="left" style="background:#F5F5F5;" + |Anti-MAS
 | align="left" style="background:#F5F5F5;" + |Unidentified cytoplasmic RNA
 | align="left" style="background:#F5F5F5;" + |
 | align="left" style="background:#F5F5F5;" + |
 |-
-|
+! align="left" style="background:#F5F5F5;" + |Anti–PM-Scl
-|
+| align="left" style="background:#F5F5F5;" + |
-|
+| align="left" style="background:#F5F5F5;" + |
-|
-|
-|-
-|
-|Anti–PM-Scl
-|
-|
 * Overlap of polymyositis and Scleroderma
-|25%
+| align="left" style="background:#F5F5F5;" + |25%
 |}
 ==References==
 {{Reflist|2}}